FI93798C - Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta - Google Patents

Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta Download PDF

Info

Publication number
FI93798C
FI93798C FI882605A FI882605A FI93798C FI 93798 C FI93798 C FI 93798C FI 882605 A FI882605 A FI 882605A FI 882605 A FI882605 A FI 882605A FI 93798 C FI93798 C FI 93798C
Authority
FI
Finland
Prior art keywords
solution
activity
mol
plasminogen activator
lysine
Prior art date
Application number
FI882605A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI93798B (fi
FI882605A7 (fi
FI882605A0 (fi
Inventor
Hans-Arnold Stoehr
Eric Paul Paques
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of FI882605A0 publication Critical patent/FI882605A0/fi
Publication of FI882605A7 publication Critical patent/FI882605A7/fi
Publication of FI93798B publication Critical patent/FI93798B/fi
Application granted granted Critical
Publication of FI93798C publication Critical patent/FI93798C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A61L2103/05—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI882605A 1987-06-05 1988-06-02 Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta FI93798C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873718889 DE3718889A1 (de) 1987-06-05 1987-06-05 Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
DE3718889 1987-06-05

Publications (4)

Publication Number Publication Date
FI882605A0 FI882605A0 (fi) 1988-06-02
FI882605A7 FI882605A7 (fi) 1988-12-06
FI93798B FI93798B (fi) 1995-02-28
FI93798C true FI93798C (fi) 1995-06-12

Family

ID=6329147

Family Applications (1)

Application Number Title Priority Date Filing Date
FI882605A FI93798C (fi) 1987-06-05 1988-06-02 Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta

Country Status (13)

Country Link
US (1) US5068106A (OSRAM)
EP (1) EP0297294B1 (OSRAM)
JP (1) JP2690944B2 (OSRAM)
KR (1) KR970005837B1 (OSRAM)
AT (1) ATE73671T1 (OSRAM)
AU (1) AU617322B2 (OSRAM)
CA (1) CA1338698C (OSRAM)
DE (2) DE3718889A1 (OSRAM)
DK (1) DK167738B1 (OSRAM)
ES (1) ES2037136T3 (OSRAM)
FI (1) FI93798C (OSRAM)
GR (1) GR3004869T3 (OSRAM)
PT (1) PT87658B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3728852C2 (de) * 1987-08-28 2003-06-18 Wilhelm Hoerrmann Arzneimittel zur Tumortherapie
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6355243B1 (en) † 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US20030122088A1 (en) * 2001-11-14 2003-07-03 Varian Semiconductor Equipment Associates, Inc. Scan methods and apparatus for ion implantation
WO2009006301A2 (en) * 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
WO2009149199A2 (en) * 2008-06-04 2009-12-10 Talecris Biotherapeutics, Inc. Composition, method and kit for preparing plasmin
JP5789521B2 (ja) 2009-03-03 2015-10-07 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン
EP3512939A1 (en) 2016-09-16 2019-07-24 Leukocare AG A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
US20190216925A1 (en) 2016-09-16 2019-07-18 Leukocare Ag A Novel Method for Stabilization of a Biopharmaceutical Drug Product During Processing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258030A (en) * 1979-03-07 1981-03-24 Zeria-Shinyaku Kogyo Kabushiki Kaisha Urokinase preparation for oral administration
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
JPS60181028A (ja) * 1984-02-29 1985-09-14 Asahi Chem Ind Co Ltd 組織プラスミノ−ゲン・アクチベ−タ−の溶解補助法
DE3687255T2 (de) * 1985-09-10 1993-05-06 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0669960B2 (ja) * 1985-11-22 1994-09-07 エーザイ株式会社 水溶性を増加したｔＰＡ含有医薬組成物
US4646292A (en) * 1985-10-01 1987-02-24 Aetna Telecommunications Laboratories Link controller
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Also Published As

Publication number Publication date
FI93798B (fi) 1995-02-28
CA1338698C (en) 1996-11-12
PT87658B (pt) 1993-03-31
FI882605A7 (fi) 1988-12-06
ES2037136T3 (es) 1993-06-16
DE3718889A1 (de) 1988-12-22
GR3004869T3 (OSRAM) 1993-04-28
DE3869230D1 (de) 1992-04-23
EP0297294A1 (de) 1989-01-04
DK304288D0 (da) 1988-06-03
US5068106A (en) 1991-11-26
DK167738B1 (da) 1993-12-13
AU617322B2 (en) 1991-11-28
FI882605A0 (fi) 1988-06-02
KR890000103A (ko) 1989-03-11
JPS63317083A (ja) 1988-12-26
DK304288A (da) 1988-12-06
EP0297294B1 (de) 1992-03-18
ATE73671T1 (de) 1992-04-15
AU1732288A (en) 1988-12-08
JP2690944B2 (ja) 1997-12-17
KR970005837B1 (ko) 1997-04-21
PT87658A (pt) 1988-07-01

Similar Documents

Publication Publication Date Title
FI93798C (fi) Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta
KR101082769B1 (ko) 저장 안정성의 액상 피브리노겐 제형
Tanaka et al. Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee
FI85334C (fi) Foerfarande foer framstaellning av en vattenbaserad, vaevnadsplasminogenaktivator (t-pa) innehaollande, koncentrerad parenterad loesning.
US4552760A (en) Method for stabilizing tissue plasminogen activator and a stable aqueous solution or powder containing the same
EP0100982A2 (en) Novel purified plasminogen activator, process for its production and thrombolytic composition containing it
FI85335C (fi) Foerfarande foer framstaellning av lyofiliserad, farmaceutisk vaevnadsplasminogenaktivator(t-pa)-komposition.
JPH0378375B2 (OSRAM)
AU785103B2 (en) Stabilized liquid preparation of the protease which activates blood coagulation factor VII, or of its proenzyme
HU198264B (en) Process for producing antithrombotic pharmaceutical compositions
US4898826A (en) Method to solubilize tissue plasminogen activator
EP0218112B1 (en) Composition containing tissue plasminogen activator
CA1283047C (en) Stabilized plasminogen activator precursor and method of producing the same
Collen et al. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model
US20050143283A1 (en) Activated protein c formulations
JPH01240186A (ja) フィブリン特異性２本鎖プラスミノーゲンアクチベーター
JPS6338327B2 (OSRAM)
US5827818A (en) Agent for subcutaneous administration of protein C
Hathiwala et al. Alteplase (TPA) for clotted dialysis catheters
GB2197195A (en) Urokinase compositions for treating thrombosis
JPH0618782B2 (ja) 組織プラスミノーゲン活性化因子製剤
JPH049334A (ja) 線溶活性増強剤
WO1990001334A1 (en) Formulations for plasminogen activator using aspartate
WO2003022997A2 (en) Human tissue urokinase type plasminogen activator formulation
EP0281579A1 (en) Cofactor of prourokinase

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed

Owner name: BEHRINGWERKE AKTIENGESELLSCHAFT